Valdo Ricca1, Giovanni Castellini, Carolina Lo Sauro, Carlo M Rotella, Carlo Faravelli. 1. Drs. Ricca, Castellini, and Lo Sauro are from the Department of Neurology and Psychiatry, University of Florence, Florence, Italy; Dr. Rotella is from the Department of Pathophysiology, Unit of Endocrinology, University of Florence, Florence, Italy; and Dr. Faravelli is from the Department of Psychology, University of Florence, Florence, Italy.
Abstract
UNLABELLED: Objective. Binge eating disorder is a serious, prevalent eating disorder that is associated with overweight. Zonisamide is an antiepileptic drug that can promote weight loss. We evaluated the efficacy and safety of zonisamide as augmentation to individual cognitive behavioral therapy in the treatment of binge eating disorder patients. DESIGN: controlled open study. PARTICIPANTS: Twenty four threshold and subthreshold binge eating disorder patients were enrolled in the cognitive behavioral therapy treatmentgroup, and 28 patients in thecognitive behavioral therapy plus zonisamidegroup. MEASUREMENTS: At the beginning (T0), at the end (T1) of treatment, and one year after the end of treatment (T2), body mass index was measured and Eating Disorder Examination-Questionnaire, Binge Eating Scale, Beck Depression Inventory, and State-Trait Anxiety Inventory were administered.Results. At T1 the cognitive behavioral therapy plus zonisamidegroup showed a higher mean reduction of body mass index, Eating Disorder Examination-Questionnaire, Beck Depression Inventory, and Binge Eating Scale scores. At T2, the cognitive behavior therapy group regained weight, while the cognitive behavioral therapy plus zonisamidegroup reduced their body mass and showed a higher reduction in binge eating frequency and Binge Eating Scale, Eating Disorder Examination-Questionnaire Restraint, and State and Trait Anxiety Inventory scores.Conclusion. The zonisamide augmentation to individual cognitive behavior therapy can improve the treatment of binge eating disorder patients, reducing body weight and the number of binge eating episodes. These results are maintained one year after the end of treatment.
RCT Entities:
UNLABELLED: Objective. Binge eating disorder is a serious, prevalent eating disorder that is associated with overweight. Zonisamide is an antiepileptic drug that can promote weight loss. We evaluated the efficacy and safety of zonisamide as augmentation to individual cognitive behavioral therapy in the treatment of binge eating disorderpatients. DESIGN: controlled open study. PARTICIPANTS: Twenty four threshold and subthreshold binge eating disorderpatients were enrolled in the cognitive behavioral therapy treatment group, and 28 patients in the cognitive behavioral therapy plus zonisamide group. MEASUREMENTS: At the beginning (T0), at the end (T1) of treatment, and one year after the end of treatment (T2), body mass index was measured and Eating Disorder Examination-Questionnaire, Binge Eating Scale, Beck Depression Inventory, and State-Trait Anxiety Inventory were administered.Results. At T1 the cognitive behavioral therapy plus zonisamide group showed a higher mean reduction of body mass index, Eating Disorder Examination-Questionnaire, Beck Depression Inventory, and Binge Eating Scale scores. At T2, the cognitive behavior therapy group regained weight, while the cognitive behavioral therapy plus zonisamide group reduced their body mass and showed a higher reduction in binge eating frequency and Binge Eating Scale, Eating Disorder Examination-Questionnaire Restraint, and State and Trait Anxiety Inventory scores.Conclusion. The zonisamide augmentation to individual cognitive behavior therapy can improve the treatment of binge eating disorderpatients, reducing body weight and the number of binge eating episodes. These results are maintained one year after the end of treatment.
Authors: Kimberly A Brownley; Nancy D Berkman; Jan A Sedway; Kathleen N Lohr; Cynthia M Bulik Journal: Int J Eat Disord Date: 2007-05 Impact factor: 4.861
Authors: V Ricca; E Mannucci; S Moretti; M Di Bernardo; T Zucchi; P L Cabras; C M Rotella Journal: Compr Psychiatry Date: 2000 Mar-Apr Impact factor: 3.735
Authors: Denise E Wilfley; R Robinson Welch; Richard I Stein; Emily Borman Spurrell; Lisa R Cohen; Brian E Saelens; Jennifer Zoler Dounchis; Mary Ann Frank; Claire V Wiseman; Georg E Matt Journal: Arch Gen Psychiatry Date: 2002-08